Saturday, March 2, 2024

CATEGORY

Takeda

Takeda’s New Oral Therapy for Eosinophilic Esophagitis Wins FDA Approval

After an initial setback in 2021, Takeda has successfully obtained FDA approval for Eohilia, marking a significant milestone as the first and only oral...

Demyelinating Polyneuropathy Treatment Takeda’s HyQvia Granted Approval by FDA

The U.S. Food and Drug Administration (FDA) has recently approved Takeda’s HyQvia as a maintenance therapy for adult patients with chronic inflammatory demyelinating...

Takeda’s Fruzaqla: A New FDA-Approved, Chemotherapy-Free Pill for Metastatic Colorectal Cancer

Takeda's Fruzaqla, a pill treatment for refractory metastatic colorectal cancer (mCRC), has been approved by the FDA. It's the first targeted therapy for an...

FDA Approves Takeda’s Fruzaqla as a Game Changer for Metastatic Colorectal Cancer Patients

The FDA has approved Takeda's Fruzaqla (fruquintinib), marking a significant advancement for patients with relapsed or refractory metastatic colorectal cancer (CRC). Fruzaqla offers a...

Latest news

Sticky Image